Medicenna Therapeutics (TSE:MDNA) Announces Earnings Results

Medicenna Therapeutics (TSE:MDNA – Get Free Report) posted its earnings results on Monday. The company reported C($0.04) EPS for the quarter, FiscalAI reports. Medicenna Therapeutics had a negative net margin of 533,640.00% and a negative return on equity of 360.29%.

Medicenna Therapeutics Trading Down 5.2%

Shares of TSE:MDNA traded down C$0.02 during midday trading on Monday, hitting C$0.36. 17,853 shares of the stock were exchanged, compared to its average volume of 82,503. The business’s 50-day moving average price is C$0.42 and its 200 day moving average price is C$0.53. Medicenna Therapeutics has a 12 month low of C$0.34 and a 12 month high of C$1.78. The company has a debt-to-equity ratio of 6.22, a quick ratio of 4.65 and a current ratio of 1.25. The stock has a market capitalization of C$33.69 million, a price-to-earnings ratio of -1.66 and a beta of 2.49.

About Medicenna Therapeutics

(Get Free Report)

Medicenna is a clinical-stage immunotherapy company developing engineered cytokine therapies designed to selectively engage the immune system to treat cancer. The Company’s most advanced program, bizaxofusp (formerly MDNA55), is a targeted IL-4 Empowered Superkine that has been evaluated in more than 130 patients across five clinical trials, including a Phase 2b study in recurrent glioblastoma. Bizaxofusp has received Fast Track designation from the FDA and Orphan Drug designation in the United States and Europe.

Read More

Earnings History for Medicenna Therapeutics (TSE:MDNA)

Receive News & Ratings for Medicenna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicenna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.